Genmab Dirección

Dirección controles de criterios 4/4

El CEO de Genmab es Jan G.J. de Winkel , nombrado en Jun 2010, tiene una permanencia de 14.42 años. compensación anual total es DKK44.30M, compuesta por 20.8% salario y 79.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.99% de las acciones de la empresa, por valor de DKK914.35M. La antigüedad media del equipo directivo y de la junta directiva es de 7.4 años y 7.7 años, respectivamente.

Información clave

Jan G.J. de Winkel

Chief Executive Officer (CEO)

DKK 44.3m

Compensación total

Porcentaje del salario del CEO	20.8%
Permanencia del CEO	14.4yrs
Participación del CEO	1.0%
Permanencia media de la dirección	7.4yrs
Promedio de permanencia en la Junta Directiva	7.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jan G.J. de Winkel en comparación con los beneficios de Genmab?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	DKK 5b
Jun 30 2024	n/a	n/a	DKK 6b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	DKK 44m	DKK 9m	DKK 4b
Sep 30 2023	n/a	n/a	DKK 4b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	DKK 42m	DKK 9m	DKK 5b
Sep 30 2022	n/a	n/a	DKK 6b
Jun 30 2022	n/a	n/a	DKK 4b
Mar 31 2022	n/a	n/a	DKK 2b
Dec 31 2021	DKK 38m	DKK 8m	DKK 3b
Sep 30 2021	n/a	n/a	DKK 3b
Jun 30 2021	n/a	n/a	DKK 3b
Mar 31 2021	n/a	n/a	DKK 6b
Dec 31 2020	DKK 37m	DKK 7m	DKK 5b
Sep 30 2020	n/a	n/a	DKK 6b
Jun 30 2020	n/a	n/a	DKK 6b
Mar 31 2020	n/a	n/a	DKK 2b
Dec 31 2019	DKK 35m	DKK 7m	DKK 2b
Sep 30 2019	n/a	n/a	DKK 2b
Jun 30 2019	n/a	n/a	DKK 1b
Mar 31 2019	n/a	n/a	DKK 1b
Dec 31 2018	DKK 28m	DKK 7m	DKK 1b
Sep 30 2018	n/a	n/a	DKK 1b
Jun 30 2018	n/a	n/a	DKK 1b
Mar 31 2018	n/a	n/a	DKK 1b
Dec 31 2017	DKK 27m	DKK 7m	DKK 1b

Compensación vs. Mercado: La compensación total ($USD6.25M) de Jan G.J. está en línea con el promedio de empresas de tamaño similar en el mercado UK ($USD5.74M).

Compensación vs. Ingresos: La compensación de Jan G.J. ha sido consistente con los resultados de la empresa en el último año.

CEO

Jan G.J. de Winkel (63 yo)

14.4yrs

Permanencia

DKK 44,300,000

Compensación

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jan G.J. de Winkel	Co-Founder	14.4yrs	DKK 44.30m	0.99% DKK 914.4m
Anthony Pagano	Executive VP & CFO	4.7yrs	DKK 19.60m	0.011% DKK 10.2m
Birgitte Stephensen	Executive VP & Chief Legal Officer	14.8yrs	DKK 10.10m	sin datos
Christopher Cozic	Executive VP & Chief People Officer	7yrs	DKK 13.20m	sin datos
Martine van Vugt	Executive VP & Chief Strategy Officer	10.8yrs	DKK 8.90m	sin datos
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	no data	DKK 800.00k	0.00061% DKK 561.8k
Judith Klimovsky	Executive VP & Chief Development Officer	7.8yrs	DKK 21.70m	0.014% DKK 12.7m
Tahamtan Ahmadi	Executive VP	3.7yrs	DKK 19.80m	0.0049% DKK 4.5m
Mijke Zachariasse	Senior Director	no data	DKK 1.10m	0.00083% DKK 764.4k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	DKK 800.00k	0.00013% DKK 119.7k
Rayne Waller	Executive VP & CTO	less than a year	sin datos	sin datos
Andrew Carlsen	Senior Director	no data	sin datos	sin datos

7.4yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0MGB es experimentado (7.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	2.8yrs	DKK 800.00k	0.00061% DKK 561.8k
Mijke Zachariasse	Senior Director	5.7yrs	DKK 1.10m	0.00083% DKK 764.4k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	2.8yrs	DKK 800.00k	0.00013% DKK 119.7k
Anders Pedersen	Non-Independent Director	21yrs	DKK 1.70m	0.011% DKK 10.6m
Elizabeth O'Farrell	Independent Director	2.7yrs	DKK 1.90m	sin datos
Deirdre Connelly	Independent Chairman of the Board	7.7yrs	DKK 2.80m	0.0091% DKK 8.3m
Rolf Hoffmann	Independent Director	7.7yrs	DKK 1.50m	0.0053% DKK 4.9m
Pernille Erenbjerg	Independent Deputy Chairman	9.8yrs	DKK 2.10m	0.0076% DKK 7.0m
Paolo Paoletti	Independent Director	9.8yrs	DKK 1.50m	0.0033% DKK 3.0m

7.7yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de 0MGB se considera experimentada (7.7 años de antigüedad promedio).

Genmab Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Genmab A/S Announces Executive Changes

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold kr.22m worth of stock

Genmab A/S, Annual General Meeting, Mar 13, 2024

Co-Founder recently sold kr.58m worth of stock

Recent updates

Third quarter 2024 earnings released: EPS: kr.19.94 (vs kr.32.60 in 3Q 2023)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold kr.22m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Full year 2023 earnings released: EPS: kr.66.64 (vs kr.84.45 in FY 2022)

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

New minor risk - Profit margin trend

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 17%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings released: EPS: kr.20.80 (vs kr.28.87 in 2Q 2022)

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

Full year 2022 earnings released: EPS: kr.84.45 (vs kr.46.00 in FY 2021)

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Co-Founder recently sold kr.57m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Second quarter 2022 earnings released: EPS: kr.28.87 (vs kr.4.68 in 2Q 2021)

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Investor sentiment improved over the past week

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

First quarter 2022 earnings released: EPS: kr.7.10 (vs kr.16.76 in 1Q 2021)

Genmab A/S Revises Earnings Guidance for 2022

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media